Tucson, AZNCT06585774Now EnrollingIRB Ready

Chronic Graft-Versus-Host Disease Clinical Trial in Tucson, AZ

Access cutting-edge chronic graft-versus-host disease treatment through this phase 3 clinical trial at a research site in Tucson. Study-provided care at no cost to qualified participants.

Sponsored by Incyte Corporation

Quick Self-Assessment

See if you qualify for this Tucson location

Preparing your pre-screening questions…

Expert Care in Tucson

Access chronic graft-versus-host disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic graft-versus-host disease treatment provided free

Apply for This Tucson Location

Check if you qualify for this chronic graft-versus-host disease clinical trial in Tucson, AZ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tucson

    Convenient for AZ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tucson site if eligible
  4. 4Begin participation

About This Chronic Graft-Versus-Host Disease Study in Tucson

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Sponsor: Incyte Corporation

Who Can Participate

Inclusion Criteria

≥ 12 years of age at the time of informed consent.
New-onset moderate or severe cGVHD, as defined by the 2014 NIH Consensus Development Project Criteria for Clinical Trials in cGVHD, requiring systemic therapy.
History of allo-HCT from any donor HLA type (related or unrelated donor with any degree of HLA matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood). Recipients of myeloablative, nonmyeloablative, or reduced-intensity conditioning are eligible.
Adequate hematologic function with ANC ≥ 0.5 × 109/L independent of growth factors for at least 7 days prior to study entry.
Willingness to avoid pregnancy or fathering children.

Exclusion Criteria

Received more than 1 prior allo-HCT. Prior autologous HCT is allowed.
Has overlap cGVHD, defined as simultaneous presence of features or characteristics of aGVHD in a patient with cGVHD.
Received more than 7 days of systemic corticosteroid treatment for cGVHD or unable to begin a prednisone dose ≥ 1.0 mg/kg per day (or methylprednisolone equivalent) for cGVHD.
Received previous systemic treatment for cGVHD, including extracorporeal photopheresis.
Systemic treatment with CNIs or mTOR inhibitors started within 2 weeks prior to C1D1.
Prior treatment with CSF-1R targeted therapies.
Active, uncontrolled bacterial, fungal, parasitic, or viral infection.
Evidence of relapse of the primary hematologic disease or treatment for relapse after the allo-HCT was performed, including DLIs for the treatment of molecular relapse.
History of acute or chronic pancreatitis.
Active symptomatic myositis.
History or current diagnosis of cardiac disease indicating significant risk of safety for participation in the study, such as uncontrolled or significant cardiac disease.
Severe renal impairment, that is, estimated CrCl \< 30 mL/min measured or calculated by Cockcroft-Gault equation in adults and Schwartz formula in pediatric participants, or endstage renal disease on dialysis.
Impaired liver function, defined as total bilirubin \> 1.5 × ULN and/or ALT and AST \> 3 × ULN in participants with no evidence of liver cGVHD.
Pregnant or breastfeeding. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tucson?

Yes, this clinical trial (NCT06585774) has an active research site in Tucson, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Graft-Versus-Host Disease Treatment Options in Tucson, AZ

If you're searching for chronic graft-versus-host disease treatment options in Tucson, AZ, this clinical trial (NCT06585774) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tucson research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic graft-versus-host disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic graft-versus-host disease clinical trials near you to find additional studies recruiting in your area.

More Atrial Fibrillation Trials in Tucson, AZ

See all atrial fibrillation clinical trials recruiting in Tucson — not just this study.

Browse Atrial Fibrillation Trials in Tucson →

Browse More Trials by Condition

Atrial Fibrillation TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Tucson?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tucson, AZ